Journal: Journal of Molecular Medicine (Berlin, Germany)

Article Title: Prosaposin in CNS health and disease, metabolic stress and exercise adaptation

doi: 10.1007/s00109-026-02643-3

Figure Lengend Snippet: Overview of prosaptide peptides derived from the saposin C domain of prosaposin (PSAP) and their tested therapeutic applications. The full saposin C sequence is shown at the top, with the neurotrophic region ( LIDNNKTEKEIL ) highlighted in green and underlined. Left panel: Sequences of various bioengineered or truncated prosaptide peptides tested in previous studies. Conservative amino acid substitutions (*) and lysine deletions (-) are indicated. Bioactivity is noted where tested. Right panel: Mapping of each prosaptide or full saposin (A–D) to specific disease-relevant therapeutic conditions, including oxidative stress, trauma/injury, ischemia, synucleinopathies, diabetes, allodynia, drug-induced toxicity, and Alzheimer’s disease-related Aβ/tau pathology. Checkboxes indicate whether the peptide has been evaluated in vitro, in vivo, or both. Peptides derived from the neurotrophic region, such as TX14(A), 769, and PS18, show diverse functional relevance across multiple disease models. Created with BioRender.com

Article Snippet: 39269584 , Taha et al. , 2024 , USA , In vivo: C57/B6L male young (3 months) mice , None , PS18 , In vivo: subcutaneous injection daily for 7 days , 2.0 mg/kg PS18 , PS18 obtained from Phoenix Pharmaceuticals (324–431) , PS18-injected animals showed modest but unpowered and independently unvalidated increases in BDNF, SNAP25, and PSD95 in cortical synapatosome fractions. Additionally, there were nonsignificant trends towards increases for SYP1, SYT1, and SAP97 in the cortical synaptosome fractions.

Techniques: Derivative Assay, Sequencing, In Vitro, In Vivo, Functional Assay

Journal: Epigenetics & Chromatin

Article Title: Site-specific regulation of histone H1 phosphorylation in pluripotent cell differentiation

doi: 10.1186/s13072-017-0135-3

Figure Lengend Snippet: Changes in the levels of phosphorylated H1 variants at pluripotency factor gene promoters correlate with their reduced expression in differentiated NT2 cells. a The levels of pS187-H1.4, pS173-H1.2/5 and pS18-H1.5 at the transcription start sites of pluripotency factor genes in NT2 cells before and after 7 days of RA treatment were assessed by ChIP-qPCR. b The levels of pS187-H1.4, pS173-H1.2/5 and pS18-H1.5 at the transcription start sites of housekeeping genes in NT2 cells before and after 7 days of RA treatment were assessed by ChIP-qPCR. Negative control ChIP assays employed non-immune rabbit immunoglobulin (rIg) in place of primary antisera. Custom antisera were used for pS187-H1.4 and pS173-H1.2/5 ChIP. Commercial antisera (Active Motif) was used for pS18-H1.5 ChIP. The data are expressed as the percent relative to input DNA (mean ± s.e.m., * p < 0.05; ** p < 0.01)

Article Snippet: The commercial antibody against pS18-H1.5 (61107) was purchased from Active Motif.

Techniques: Expressing, ChIP-qPCR, Negative Control

Journal: Epigenetics & Chromatin

Article Title: Site-specific regulation of histone H1 phosphorylation in pluripotent cell differentiation

doi: 10.1186/s13072-017-0135-3

Figure Lengend Snippet: The activity of CDK9, but not CDK2, is required for H1.4-S187 phosphorylation. a Pluripotent NT2 cells were treated for increasing intervals with 10 µM NU6140 or 1 µM flavopiridol to preferentially inhibit CDK2 and CDK9, respectively. The global abundance of pS18-H1.5 and pS187-H1.4 was assessed by immunoblotting whole-cell lysates. The blot for histone H3 serves as a loading control. The 0 h time points provide a solvent control (DMSO). Commercial antisera (Active Motif) was used to detect pS18-H1.5. b HeLa cells were treated with DMSO or 10 μM NU6140 for 1 h. The loss of CDK2-mediated phosphorylation of CDK7-T170 was assessed by immunoblotting whole-cell lysates with the indicated antisera. c HeLa cells were treated with DMSO or 1 μM flavopiridol for 1 h. Altered phosphorylation in the CTD heptad repeats of RNAP II was assessed by immunoblotting whole-cell lysates with the indicated antisera. The numbers below each panel indicate densitometry for the treated samples relative to the respective control sample

Article Snippet: The commercial antibody against pS18-H1.5 (61107) was purchased from Active Motif.

Techniques: Activity Assay, Phospho-proteomics, Western Blot, Control, Solvent